## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tesamorelin-sciatica`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tesamorelin-sciatica/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tesamorelin-sciatica` v2 · content_hash `2c76437264313674…` · thread_head genesis · 26 DIVs
- **thesis (c1):** One ongoing phase 2 trial tests tesamorelin for peripheral nerve injury recovery.
  - c3 [human/active] ARA-290 improved neuropathic symptoms and corneal nerve fiber density in human small fiber neuropathy trials.
  - c2 [preclinical/active] Rat studies show BPC-157 improved axonal regeneration and functional recovery after sciatic nerve transection.
  - c4 [preclinical/active] TB-500 improved sciatic nerve function in diabetic neuropathy animal models.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-sciatica/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-sciatica/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tesamorelin-sciatica`
- **title:** Tesamorelin for Sciatica: Evidence on Repair Layers vs Symptom Suppression
- **url:** https://miscsubjects.com/a/tesamorelin-sciatica
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:26.023Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Sciatica

Sciatica involves nerve pain along the sciatic nerve, often from disc herniation or spinal stenosis compressing a nerve root. The nerve signals damage or compression. Suppressing pain signals does not address the compression or the underlying tissue breakdown. Repair pathways must outpace ongoing degeneration for symptoms to resolve long-term. Mechanical factors like excess visceral fat can add compressive load on the lumbar spine.

## Why Tesamorelin might help you

1. You have Sciatica — breakdown is outpacing repair.
2. Therefore for you: If visceral fat or growth hormone axis issues contribute to mechanical load or poor tissue turnover, Tesamorelin is discussed because it targets the GH axis and visceral fat reduction — not because it masks pain.
3. This article centers Tesamorelin; see other sections for BPC-157, TB-500, ARA-290 — different layers, same condition.

## Why BPC-157 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Poor blood supply at injury sites, weak collagen organization, slow tissue turnover.
3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

## Why TB-500 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

## Why ARA-290 might help you

1. You have Sciatica — breakdown is outpacing repair.
2. What keeps failing: Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.
3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

## How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.
- Tesamorelin → GH axis / visceral fat
- BPC-157 → structure / tissue
- TB-500 → inflammation clearance / repair-cell migration
- ARA-290 → nerve / innervation

Primary focus of this slug: Tesamorelin. Others are in scope because the same condition breaks down on multiple layers.

## What the evidence actually shows

Human data on Tesamorelin for sciatica is absent. One ongoing phase 2 trial tests it for peripheral nerve injury recovery (human, recruiting). Phase 3 HIV trials showed visceral fat reduction but listed back pain among adverse events (human). BPC-157 rat studies on transected sciatic nerve showed faster axonal regeneration, improved motor action potentials, and better sciatic functional index versus controls (preclinical). TB-500 (thymosin beta-4) mouse studies in diabetic neuropathy improved sciatic nerve conduction velocity and function (preclinical). ARA-290 human trials in sarcoidosis small fiber neuropathy patients improved neuropathic symptom scores and corneal nerve fiber density versus placebo (human). No human trials link any of these directly to sciatica resolution.

## What scientists say

Researchers note Tesamorelin's selectivity for the GHRH receptor and visceral fat effects in HIV populations. Animal nerve injury models for BPC-157 and TB-500 demonstrate structural and functional recovery endpoints. ARA-290 studies highlight innate repair receptor activation leading to measurable small fiber regrowth in human neuropathy cohorts.

## What people say on Reddit

Direct reports tying Tesamorelin or the other peptides to sciatica outcomes are scarce in public forums. General peptide discussions focus on recovery anecdotes without controlled verification.

## What people say on X

Public posts on X show limited specific mentions of these compounds for sciatica. Most references stay at the level of general interest in nerve repair research.

## What we do not know

Long-term human outcomes for any of these compounds in sciatica remain unknown. No head-to-head trials exist. Weight loss effects from Tesamorelin on spinal load are inferred from body composition changes but untested in sciatica cohorts. Human dosing, duration, and combination safety data are absent.

## Safety and limits

Tesamorelin phase 3 data reported joint and muscle symptoms in some participants (human). Animal nerve studies for BPC-157 and TB-500 showed no major toxicity signals in short-term models. ARA-290 trials reported good tolerability in neuropathy patients (human). All remain investigational outside approved indications. Evidence grading separates human trials (limited to ARA-290 neuropathy and Tesamorelin nerve injury trial) from preclinical animal work and absent direct anecdotes for this condition.

## Claims (4)

- **c1** [human w=0.8] One ongoing phase 2 trial tests tesamorelin for peripheral nerve injury recovery.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [preclinical w=0.5] Rat studies show BPC-157 improved axonal regeneration and functional recovery after sciatic nerve transection.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] ARA-290 improved neuropathic symptoms and corneal nerve fiber density in human small fiber neuropathy trials.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [preclinical w=0.5] TB-500 improved sciatic nerve function in diabetic neuropathy animal models.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (4 atoms · 8 edges)
- full graph: https://miscsubjects.com/api/articles/tesamorelin-sciatica/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `ea941231b21b23d0`

### s1 · clinical_trial · ok
- title: Tesamorelin for Peripheral Nerve Injury
- url: https://www.withpower.com/trial/phase-3-peripheral-nerve-injuries-5-2018-b26fd
- summary: Phase 2 trial recruiting for tesamorelin in peripheral nerve injury recovery.
- quote: This trial tests whether tesamorelin, a growth hormone-releasing factor, can aid recovery from peripheral nerve injuries, such as an ulnar nerve cut at the wrist.
- claim_ids: c1
- hash: `7aa30a3d6623a375`

### s2 · pubmed · ok
- title: Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury
- url: https://pubmed.ncbi.nlm.nih.gov/19903499/
- summary: Rat study on BPC-157 improving transected sciatic nerve healing and function.
- quote: BPC 157 markedly improved rat sciatic nerve healing.
- claim_ids: c2
- hash: `aded0bf9f7212326`

### s3 · pubmed · ok
- title: ARA 290 for treatment of small fiber neuropathy in sarcoidosis
- url: https://pubmed.ncbi.nlm.nih.gov/24555851/
- summary: Human trial showing ARA-290 benefits in small fiber neuropathy symptoms.
- quote: ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients.
- claim_ids: c3
- hash: `6a32108c64dccd62`

### s4 · pubmed · ok
- title: Thymosin β4 Promotes the Recovery of Peripheral Neuropathy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/
- summary: Animal study on thymosin beta-4 improving sciatic nerve parameters in neuropathy model.
- quote: The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.
- claim_ids: c4
- hash: `ea941231b21b23d0`

## Provenance (2 model passes)
- chain valid: yes · head: `ac26d2570d0ba688`

- write · grok/grok-4.3 · 2026-06-29T23:14 · hash `c0289d9a02a6`
- voxel_divide · owner · 2026-07-17T02:42 · hash `ac26d2570d0b`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-sciatica/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tesamorelin-sciatica/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-sciatica","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-sciatica|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-sciatica|tier|assertion`
- **iMessage ask:** `tesamorelin-sciatica|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tesamorelin-sciatica`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-sciatica/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-sciatica/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*